|Scientific Subdivisions | The Journal of Molecular Diagnostics
Contact AMP | Sign In | Join / Renew | Go To CHAMP
March 20, 2015: AMP's feedback urges FDA to focus its attention on helping to ensure the performance characteristics of NGS instruments, reagents, and related software.
March 4, 2015: These models are available for free and can be used to effectively communicate the cost and value of genomic sequencing procedure services to Medicare and commerical payers.
February 20, 2015: In its verbal comments to the FDA, AMP recommends FDA focus on evaluating and ensuring consistent performance of NGS diagnostic tests.
February 12, 2015: AMP Working Group recommends that laboratories develop individual policies for analysis and reporting of known and predicted incidental findings.
February 12, 2015: AMP and CAP signed a memorandum of understanding to foster synergies between the sub-specialty of molecular pathology and the general practice of pathology.
February 10, 2015: Updated position on Direct Access Genetic testing, concludes that clinically meaningful tests could benefit patients and consumers and should be made to the public, but only if certain conditions are met.
January 29, 2015: AMP expresses numerous concerns with FDA's proposed draft framework including its interference with the practice of medicine and its potential impact on patient access to vital molecular testing services that AMP members and their laboratories offer.
January 12, 2015: CAP, IASLC, and AMP have teamed up to revise the evidence-based guideline, "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors."
January 8, 2015: White Paper addresses the convergence of regulatory and reimbursement forces that threaten patient care. "AMP is addressing the consequences of this gathering perfect storm of regulatory and reimbursement challenges directed against molecular diagnostic testing with recommendations designed to preserve patient access to these essential medical services" said AMP President, Janina Longtine, MD. More information...
January 8, 2015: FDA's Public Workshop - Framework for Regulatory Oversight of LDTs, includes presentations by ten AMP members. Message emphasizes optimization of patient care through molecular diagnostics.
January 5, 2015: AMP responded to specific questions posed by the U.S. Energy and Commerce Committee regarding LDPs and spelled out clear recommendations for ensuring patient care.